Oxypeucedanin

Oxypeucedanin is a furanocoumarin derivative found in Angelica dahurica. Oxypeucedanin is an orally active PI3K/AKT/NF-κB, MAPK, and ROS inhibitor. Oxypeucedanin induces cell cycle arrest and apoptosis. Oxypeucedanin inhibits hKv1.5 channel currents (IC₅₀: 76 nM). Oxypeucedanin exhibits anticancer, anti-inflammatory, antioxidant and antiarrhythmic activities^{[1][2][3][4][5]}. IC50 & Target:IC50: HKv1.5 current; apoptosis^[1] In Vitro:oxypeucedanin (1-1000 nM) inhibits hKv1.5 channel currents expressed in the mouse Ltk^- cell lines in a concentration-dependent manner (IC₅₀: 76 nM)^[1].
oxypeucedanin (0.1-1 μM) prolongs the action potential duration (APD) of rat atrial and ventricular myocytes in a concentration-dependent manner^[1].
Oxypeucedanin (25-100 μM, 24-72 h) inhibits the viability of human prostate cancer DU145 cells and induces apoptosis in a time- and dose-dependent manner^[2].
Oxypeucedanin (25-100 μM, 24-48 h) induces G2-M arrest in DU145 cell cycle progression in a dose-dependent manner^[2].
Oxypeucedanin (6.25-12.5 μM, 7-13 h) inhibits the expression of inflammatory factors IL-6, IL-1β, TNF-α, iNOS, COX-2 and the production of ROS in RAW264.7 cells^[3].
Oxypeucedanin (6.25-12.5 μM, 2 h) inhibits the PI3K/AKT/NF-κB and MAPK signaling pathways in RAW264.7 cells^[3].
In Vivo:Oxypeucedanin (10/15 mg/kg, i.p., once) inhibits lung inflammatory damage in a lipopolysaccharide (LPS)-induced acute lung injury (ALI) mouse model in a dose-dependent manner and induces the integrity of the lung air-blood barrier in mice^[3].
Oxypeucedanin (13.5 mg/kg, p.o.) alleviates the severity of collagen-induced arthritis (CIA) model in rats^[4].